Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Gliomas are the most common and malignant intracranial tumors in adults. Recent studies
have revealed the significance of functional genomics for glioma pathophysiological studies …

Background Terminology to describe extent of resection in glioblastoma is inconsistent
across clinical trials. A surgical classification system was previously proposed based upon …

The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical
resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 …

Primary CNS tumours refer to a heterogeneous group of tumours arising from cells within the
CNS, and can be benign or malignant. Malignant primary brain tumours remain among the …

Surgical resection represents the standard of care in diffuse glioma, and more extensive
tumour resection appears to be associated with favourable outcome. Up to now, terminology …

Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in
all of oncology. Although advances have been made in the treatment of GBM, encouraging …

Glioblastoma (GBM) is the most common and lethal tumor of the central nervous system. The
natural history of treated GBM remains very poor with 5-year survival rates of 5%. Survival …

Antisense miRNA oligonucleotides against miR-21 (AMO-21) have a therapeutic potential
for treatment of glioblastoma. However, glioblastoma-targeted delivery through systemic …